* Mink Therapeutics Inc INKT.OQ INKT.O is expected
to report
results on November 14 for the period ending September 30 2024
*
* LSEG's mean analyst estimate for Mink Therapeutics Inc is
for a
loss of 8 cents per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Mink
Therapeutics
Inc is 8.00, above its last closing price of $0.75.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jan. 1 0001 -0.10 -0.10 -0.07 Beat 30
Mar. 31 0001 -0.16 -0.15 -0.11 Beat 28.3
Dec. 31 2023 -0.15 -0.16 Missed -4.3
Sep. 30 2023 -0.18 -0.18 -0.15 Beat 17.8
Jun. -0.19 -0.20 -0.18 Beat 8.9
30 2023
Mar. 31 2023 -0.25 -0.24 -0.17 Beat 28.4
Jan. 1 0001 -0.21 -0.23 Missed -9.5
Sep. 30 2022 -0.23 -0.23 -0.19 Beat 18.3
This summary was machine generated November 12 at 14:13 GMT.
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)